首页 > 最新文献

Acta Hepatologica Japonica最新文献

英文 中文
基調講演 基调讲演
Q4 Medicine Pub Date : 2022-04-20 DOI: 10.3388/jspaci.32.407
{"title":"基調講演","authors":"","doi":"10.3388/jspaci.32.407","DOIUrl":"https://doi.org/10.3388/jspaci.32.407","url":null,"abstract":"","PeriodicalId":35810,"journal":{"name":"Acta Hepatologica Japonica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41808699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of drug-induced liver injury causing cirrhosis in the short term by the treatment of amiodarone 胺碘酮治疗致药物性肝损伤短期肝硬化1例
Q4 Medicine Pub Date : 2022-04-01 DOI: 10.2957/kanzo.63.203
Hikari Kobayashi, H. Nagai, T. Mukozu, Kunihide Mori, Gou Watanabe, Naoyuki Yoshimine, Kojiro Kobayashi, Y. Ogino, Teppei Matsui, Yasuko Daido, N. Wakui, Koichi Momiyama, Y. Igarashi
The patient was a man in his 70s who had been attending our hospitalʼs Department of Cardiology for an old myocardial infarction; however, in 20XX, a defibrillator was implanted due to cardiac arrest caused by ven-tricular fibrillation, and amiodarone was used to prevent arrhythmia. He was referred to our department 1 year and 8 months after taking amiodarone due to liver damage, and an abdominal simple CT examination showed high absorption of the liver. He was diagnosed with drug-induced liver injury due to amiodarone and was ad-vised to discontinue the drug; however, the drug administration was continued because there was no alterna-tive drug. He was diagnosed with cirrhosis four years and one month after starting amiodarone, and he stopped taking it. He died of liver failure six months later. Because amiodarone-induced drug-induced liver injury can quickly progress to cirrhosis, it is important to monitor blood levels of amiodarone and adjust the dose.
患者是一位70多岁的老人,因老年性心肌梗死到我院心内科就诊;然而,在20XX年,由于心室颤动导致心脏骤停,植入了除颤器,并使用胺碘酮预防心律失常。患者因肝损伤服用胺碘酮1年8个月后转到我科就诊,腹部单纯CT检查显示肝脏高吸收。他被诊断为胺碘酮引起的药物性肝损伤,并被建议停药;然而,由于没有替代药物,药物管理仍在继续。在开始服用胺碘酮四年零一个月后,他被诊断出患有肝硬化,并停止服用。六个月后,他死于肝功能衰竭。由于胺碘酮引起的药物性肝损伤可迅速发展为肝硬化,因此监测血液中胺碘酮的水平并调整剂量是很重要的。
{"title":"A case of drug-induced liver injury causing cirrhosis in the short term by the treatment of amiodarone","authors":"Hikari Kobayashi, H. Nagai, T. Mukozu, Kunihide Mori, Gou Watanabe, Naoyuki Yoshimine, Kojiro Kobayashi, Y. Ogino, Teppei Matsui, Yasuko Daido, N. Wakui, Koichi Momiyama, Y. Igarashi","doi":"10.2957/kanzo.63.203","DOIUrl":"https://doi.org/10.2957/kanzo.63.203","url":null,"abstract":"The patient was a man in his 70s who had been attending our hospitalʼs Department of Cardiology for an old myocardial infarction; however, in 20XX, a defibrillator was implanted due to cardiac arrest caused by ven-tricular fibrillation, and amiodarone was used to prevent arrhythmia. He was referred to our department 1 year and 8 months after taking amiodarone due to liver damage, and an abdominal simple CT examination showed high absorption of the liver. He was diagnosed with drug-induced liver injury due to amiodarone and was ad-vised to discontinue the drug; however, the drug administration was continued because there was no alterna-tive drug. He was diagnosed with cirrhosis four years and one month after starting amiodarone, and he stopped taking it. He died of liver failure six months later. Because amiodarone-induced drug-induced liver injury can quickly progress to cirrhosis, it is important to monitor blood levels of amiodarone and adjust the dose.","PeriodicalId":35810,"journal":{"name":"Acta Hepatologica Japonica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41846744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A case of an elderly patient with chronic hepatitis C exacerbated by chemotherapy for malignant lymphoma and improved by direct-acting antivirals therapy 一例老年慢性丙型肝炎患者因恶性淋巴瘤化疗而加重,并通过直接抗病毒治疗得到改善
Q4 Medicine Pub Date : 2022-04-01 DOI: 10.2957/kanzo.63.196
Yuma Aoki, A. Kinoshita, Akiyuki Osawa, T. Kano, Yuko Sato, Yuki Mitsuyoshi, K. Koike, M. Saruta
{"title":"A case of an elderly patient with chronic hepatitis C exacerbated by chemotherapy for malignant lymphoma and improved by direct-acting antivirals therapy","authors":"Yuma Aoki, A. Kinoshita, Akiyuki Osawa, T. Kano, Yuko Sato, Yuki Mitsuyoshi, K. Koike, M. Saruta","doi":"10.2957/kanzo.63.196","DOIUrl":"https://doi.org/10.2957/kanzo.63.196","url":null,"abstract":"","PeriodicalId":35810,"journal":{"name":"Acta Hepatologica Japonica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42843481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Liver biopsy implementation rate for diagnosis of NASH in Japan -analysis of big data of health insurance claims- 日本肝活检诊断NASH的执行率-健康保险理赔大数据分析-
Q4 Medicine Pub Date : 2022-04-01 DOI: 10.2957/kanzo.63.211
Aya Sugiyama, Akemi Kurisu, T. Kumada, J. Tanaka
{"title":"Liver biopsy implementation rate for diagnosis of NASH in Japan -analysis of big data of health insurance claims-","authors":"Aya Sugiyama, Akemi Kurisu, T. Kumada, J. Tanaka","doi":"10.2957/kanzo.63.211","DOIUrl":"https://doi.org/10.2957/kanzo.63.211","url":null,"abstract":"","PeriodicalId":35810,"journal":{"name":"Acta Hepatologica Japonica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47148852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Examination of factors contributing to the prognosis in TACE treatment of hepatocellular carcinoma 肝细胞癌TACE治疗中影响预后因素的探讨
Q4 Medicine Pub Date : 2022-04-01 DOI: 10.2957/kanzo.63.187
Toshimitsu Yasui, Yujiro Adachi, Shin Satake, Kenji Aoi, Hisashi Jou, Naruyasu Kakita, Y. Yamada, T. Tabuchi, K. Katayama
{"title":"Examination of factors contributing to the prognosis in TACE treatment of hepatocellular carcinoma","authors":"Toshimitsu Yasui, Yujiro Adachi, Shin Satake, Kenji Aoi, Hisashi Jou, Naruyasu Kakita, Y. Yamada, T. Tabuchi, K. Katayama","doi":"10.2957/kanzo.63.187","DOIUrl":"https://doi.org/10.2957/kanzo.63.187","url":null,"abstract":"","PeriodicalId":35810,"journal":{"name":"Acta Hepatologica Japonica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46728807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of hemochromatosis due to heterozygous mutations in TfR2 TfR2杂合突变致血色素沉着症1例
Q4 Medicine Pub Date : 2022-03-01 DOI: 10.2957/kanzo.63.151
Hitoshi Nishio, Yuichi Honma, Keiichiro Kumamoto, Y. Toki, Kahori Morino, Shinji Oe, Koichiro Miyagawa, Michihiko Shibata, S. Abe, Y. Tatsumi, K. Ikuta, H. Hayashi, M. Harada
{"title":"A case of hemochromatosis due to heterozygous mutations in TfR2","authors":"Hitoshi Nishio, Yuichi Honma, Keiichiro Kumamoto, Y. Toki, Kahori Morino, Shinji Oe, Koichiro Miyagawa, Michihiko Shibata, S. Abe, Y. Tatsumi, K. Ikuta, H. Hayashi, M. Harada","doi":"10.2957/kanzo.63.151","DOIUrl":"https://doi.org/10.2957/kanzo.63.151","url":null,"abstract":"","PeriodicalId":35810,"journal":{"name":"Acta Hepatologica Japonica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47790985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dynamic contrast-enhanced CT at the early stage confirms two cases of acute liver failure due to acute-onset autoimmune hepatitis with extensive liver necrosis 早期动态增强CT证实2例急性自身免疫性肝炎并发广泛性肝坏死引起的急性肝功能衰竭
Q4 Medicine Pub Date : 2022-03-01 DOI: 10.2957/kanzo.63.158
Tsunamasa Watanabe, Po-sung Chu, T. Ehira, Y. Hasegawa, N. Hattori, M. Shinoda, H. Ikeda, Hanako Tsujikawa, H. Obara, Masaki Hara, Tatsuya Suzuki, K. Matsunaga, C. Okuse, F. Itoh
[Case 1] A 54-year-old female presented with severe liver damage. During diagnosis, contrast-enhanced CT enhanced the area of hypoattenuation on unenhanced CT in the arterial phase, after which the enhanced effect was prolonged to the equilibrium phase. Then, we started immunosuppressive therapy based on the results, including corticosteroid administration, and her hepatitis subsided. [Case 2] A 57-year-old female also presented with severe hepatitis. Contrast-enhanced CT findings were similar to those of Case 1. Since hepatic encephalo-pathy developed and worsened to degree IV, a brain-dead liver transplant was conducted on the 21st day. Nev-ertheless, histological diagnosis was challenging in both cases. Therefore, when unenhanced CT shows hetero-geneous hypoattenuation in the liver and contrast-enhanced CT shows a characteristic blood flow disorder, acute-onset autoimmune hepatitis and corticosteroid treatment should be considered, including in complex se-rological or histological case diagnoses.
[病例1]54岁女性,表现为严重肝损害。诊断时,增强CT在动脉期增强未增强CT低衰减区域,增强后增强效果延长至平衡期。然后,我们根据结果开始免疫抑制治疗,包括皮质类固醇治疗,她的肝炎消退了。[病例2]一名57岁女性也表现为重度肝炎。CT增强表现与病例1相似。因肝性脑病发展并恶化至IV级,于第21天行脑死肝移植。然而,两例患者的组织学诊断都具有挑战性。因此,当非增强CT显示肝脏非均匀性低衰减,而增强CT显示特征性血流障碍时,应考虑急性发作的自身免疫性肝炎和皮质类固醇治疗,包括复杂的血清学或组织学病例诊断。
{"title":"Dynamic contrast-enhanced CT at the early stage confirms two cases of acute liver failure due to acute-onset autoimmune hepatitis with extensive liver necrosis","authors":"Tsunamasa Watanabe, Po-sung Chu, T. Ehira, Y. Hasegawa, N. Hattori, M. Shinoda, H. Ikeda, Hanako Tsujikawa, H. Obara, Masaki Hara, Tatsuya Suzuki, K. Matsunaga, C. Okuse, F. Itoh","doi":"10.2957/kanzo.63.158","DOIUrl":"https://doi.org/10.2957/kanzo.63.158","url":null,"abstract":"[Case 1] A 54-year-old female presented with severe liver damage. During diagnosis, contrast-enhanced CT enhanced the area of hypoattenuation on unenhanced CT in the arterial phase, after which the enhanced effect was prolonged to the equilibrium phase. Then, we started immunosuppressive therapy based on the results, including corticosteroid administration, and her hepatitis subsided. [Case 2] A 57-year-old female also presented with severe hepatitis. Contrast-enhanced CT findings were similar to those of Case 1. Since hepatic encephalo-pathy developed and worsened to degree IV, a brain-dead liver transplant was conducted on the 21st day. Nev-ertheless, histological diagnosis was challenging in both cases. Therefore, when unenhanced CT shows hetero-geneous hypoattenuation in the liver and contrast-enhanced CT shows a characteristic blood flow disorder, acute-onset autoimmune hepatitis and corticosteroid treatment should be considered, including in complex se-rological or histological case diagnoses.","PeriodicalId":35810,"journal":{"name":"Acta Hepatologica Japonica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48248212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A pre-existing case of HBV infection with elevated HBV DNA after COVID-19 pneumonia treatment COVID-19肺炎治疗后HBV DNA升高的既往HBV感染病例
Q4 Medicine Pub Date : 2022-03-01 DOI: 10.2957/kanzo.63.170
Takeshi Matsui, Kazunari Tanaka, R. Minami, K. Tsuji, Jong‐Hon Kang, A. Katanuma, Shinsuke Onishi
The patient presented with fever and appetite loss. Computed tomography (CT) revealed a moderate grade 2 pneumonia. Besides, further blood examination showed his HB antigen as negative, anti-HBs/c anti-body as positive, and HBV DNA level as 1.0 LIU/mL. Therefore, he was diagnosed with COVID-19. Administered treatments comprised oxygen inhalation and steroid therapy, including pulses, remdesivir, and baricitinib, which improved pneumonia. Interestingly, one month posttreatment, his HBV DNA level in-creased to 1.4 LIU/mL, followed by a further increase to 1.7 LIU/Ml, showing an improvement. Tenofovir alafenamide fumarate was thus administered. In clinical practice, immunosuppressive therapy is used for patients with moderate-to-severe COVID-19 pneumo-nia. However, close attention should also be paid to the elevation of blood HBV DNA levels during and after treatment.
病人表现为发烧和食欲不振。计算机断层扫描(CT)显示中度2级肺炎。进一步的血液检查显示他的乙肝抗原为阴性,抗-HBs/c抗体为阳性,HBV DNA水平为1.0 LIU/mL。因此,他被诊断为新冠肺炎。给药治疗包括吸氧和类固醇治疗,包括脉冲、瑞德西韦和巴里西替尼,这些药物可以改善肺炎。有趣的是,治疗一个月后,他的HBV DNA水平增加到1.4 LIU/mL,随后进一步增加到1.7 LIU/mL。因此给药富马酸替诺福韦。在临床实践中,免疫抑制疗法用于中度至重度新冠肺炎肺炎患者。然而,在治疗期间和治疗后,还应密切注意血液HBV DNA水平的升高。
{"title":"A pre-existing case of HBV infection with elevated HBV DNA after COVID-19 pneumonia treatment","authors":"Takeshi Matsui, Kazunari Tanaka, R. Minami, K. Tsuji, Jong‐Hon Kang, A. Katanuma, Shinsuke Onishi","doi":"10.2957/kanzo.63.170","DOIUrl":"https://doi.org/10.2957/kanzo.63.170","url":null,"abstract":"The patient presented with fever and appetite loss. Computed tomography (CT) revealed a moderate grade 2 pneumonia. Besides, further blood examination showed his HB antigen as negative, anti-HBs/c anti-body as positive, and HBV DNA level as 1.0 LIU/mL. Therefore, he was diagnosed with COVID-19. Administered treatments comprised oxygen inhalation and steroid therapy, including pulses, remdesivir, and baricitinib, which improved pneumonia. Interestingly, one month posttreatment, his HBV DNA level in-creased to 1.4 LIU/mL, followed by a further increase to 1.7 LIU/Ml, showing an improvement. Tenofovir alafenamide fumarate was thus administered. In clinical practice, immunosuppressive therapy is used for patients with moderate-to-severe COVID-19 pneumo-nia. However, close attention should also be paid to the elevation of blood HBV DNA levels during and after treatment.","PeriodicalId":35810,"journal":{"name":"Acta Hepatologica Japonica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47159587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Clinical features of hepatic dysfunction caused by immune checkpoint inhibitors and treatment of refractory cases 免疫检查点抑制剂引起肝功能不全的临床特点及难治性病例的治疗
Q4 Medicine Pub Date : 2022-03-01 DOI: 10.2957/kanzo.63.107
Tomoko Tadokoro, J. Tani, Kei Takuma, Mai Nakahara, K. Oura, Koji Fujita, Shima Mimura, M. Ono, A. Morishita, Tsutomu Masaki
{"title":"Clinical features of hepatic dysfunction caused by immune checkpoint inhibitors and treatment of refractory cases","authors":"Tomoko Tadokoro, J. Tani, Kei Takuma, Mai Nakahara, K. Oura, Koji Fujita, Shima Mimura, M. Ono, A. Morishita, Tsutomu Masaki","doi":"10.2957/kanzo.63.107","DOIUrl":"https://doi.org/10.2957/kanzo.63.107","url":null,"abstract":"","PeriodicalId":35810,"journal":{"name":"Acta Hepatologica Japonica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45391853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and effectiveness of glecaprevir/pibrentasvir in patients with chronic hepatitis C or compensated cirrhosis in daily clinical practice: a drug-use results survey 格列卡韦/皮布伦他韦在慢性丙型肝炎或代偿性肝硬化患者日常临床应用中的安全性和有效性:药物使用结果调查
Q4 Medicine Pub Date : 2022-03-01 DOI: 10.2957/kanzo.63.120
S. Mochida, Toshihisa Matsuzaki, K. Kawana, Kaoru Ohchi, R. Sakuma, M. Kurosaki
{"title":"Safety and effectiveness of glecaprevir/pibrentasvir in patients with chronic hepatitis C or compensated cirrhosis in daily clinical practice: a drug-use results survey","authors":"S. Mochida, Toshihisa Matsuzaki, K. Kawana, Kaoru Ohchi, R. Sakuma, M. Kurosaki","doi":"10.2957/kanzo.63.120","DOIUrl":"https://doi.org/10.2957/kanzo.63.120","url":null,"abstract":"","PeriodicalId":35810,"journal":{"name":"Acta Hepatologica Japonica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41368196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Hepatologica Japonica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1